Xbrane & STADA have signed an exclusive license agreement with Valorum Biologics to commercialize Xlucane, biosimilar of ranibizumab, across the US
As per the agreement, both companies will complete the regulatory approval process; Xbrane to handle commercial manufacturing & supply. Post approval, Valorum will take care of sales, marketing & other commercial activities of LUCAMZI (Xlucane)
Valorum will make a payment of $45M as license fee incl. regulatory & sales milestones plus sales-based royalties, to be shared b/w both. Furthermore, as per separate agreement, product will be supplied by Xbrane to Valorum at double-digit mark-up over cost of goods sold (CoGS)
Ref: Xbrane | Image: Xbrane
Related News:- Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
